L-PAM

(redirected from melphalan)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
AcronymDefinition
L-PAMMelphalan
References in periodicals archive ?
Food and Drug Administration (FDA) for melphalan "as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation.
Primary cancer cells from patients representing twenty different types of cancers have been studied, including multiple myeloma, with melflufen showing 50- to 100-fold higher anti-tumor potency over melphalan.
The patient was treated with intravenous melphalan for two consecutive days at a total dose of 140 mg/[m.
In the largest of these studies, a Boston group treated 312 of 701 evaluated patients with high-dose melphalan followed by ASCT Patients were excluded if they were over age 80 or had uncompensated heart failure, left ventricular ejection fraction <40%, persisting pleural effusion, systolic pressure <90 mm Hg, oxygen saturation <95%, or a performance status [greater than or equal to] 3.
The patients then receive high-dose therapy with melphalan in varying doses, depending on the patient's age.
This treatment was followed by mobilization with cyclophosphamide, stem cell collection, ASCT, and melphalan 200 mg/[m.
Cancer patient Mary Doswell, of Lammas Close, Husbands Bosworth, died in Coventry's Walsgrave Hospital after her GP, Frederick David Roberts, prescribed too much of the powerful anti-cancer drug Melphalan.
A typical physician is trained to deal with toxins and steroids, melphalan to whack the myeloma here, dexamethasone to boost the marrow there.
SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has initiated a pivotal trial of Captisol-enabled([R]), propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma.
The approval was grounded on Phase III studies, comprising the FIRST trial which evaluated a continuous Revlimid/Dex combo until disease progression versus melphalan, prednisone and thalidomide in 1,623 newly- diagnosed patients who were not candidates for stem cell transplant.
The investment will finance a phase II clinical program in multiple myeloma with the novel cytosuperior compound melflufen (previously known as J1 in peer reviewed journals), an enhanced cytotoxic alkylating agent based on melphalan.
Maloney's study so far received melphalan 200 mg/[m.